IntegraGen today announced that it has successfully completed a capital increase with cancellation of preferential subscription rights, reserved for a category of investors in the amount of € 3.7 million.
Objectives of Fundraising
The funds received will permit IntegraGen to accelerate its development by supporting the deployment of the following new activities:
- Launch of kit production miRpredX: commercialization of a predictive diagnostic kit for response to anti-EGFR treatment for patients with metastatic colorectal cancer.
- Development of ICE (Interpretation of Clinical Exome), a software tool for interpreting clinical genomics data in cancer patients
The funds will also enable IntegraGen’s genomic services platforms to be strengthened with newer technologies.